Tesamorelin
One of the few compounds in this space with real Phase III human data and an actual regulatory approval — for one specific use, in one specific country. The contrast with BPC-157 is the point of this article.
Tesamorelin (Egrifta, TH9507)
Synthetic GHRH (growth hormone-releasing hormone) analogue
Metabolic (visceral fat) · Endocrine (growth hormone axis)
Yes — real Phase III RCT data, 412 and pooled 806 participants
FDA-approved (US) for one indication; no MHRA or EMA authorisation
5 October 2026
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the signal the hypothalamus normally uses to tell the pituitary gland to release growth hormone. It's given by daily subcutaneous injection, and was developed specifically to address a defined medical problem: excess visceral abdominal fat (lipodystrophy) in people living with HIV, a recognised complication of the infection and its treatment.
HIV-associated lipodystrophy was, and remains, a real unmet clinical need with limited treatment options. Stimulating the body's own growth hormone release offered a plausible, mechanistically grounded way to address the specific fat-distribution problem seen in this population — and unlike many research peptides, this hypothesis was actually carried all the way through registered, controlled human trials.
Established
Tesamorelin binds GHRH receptors in the pituitary gland, stimulating release of endogenous growth hormone. This mechanism is well-characterised and is the basis on which its approved effect on visceral fat was demonstrated in trials.
Not established for other uses
Broader claims about general fat loss, anti-ageing, or athletic performance extend beyond the mechanism actually tested in the approved indication, and are not supported by the trial evidence below.
Laboratory / In-vitro
Receptor-binding and endocrine pharmacology studies supporting the GHRH mechanism.
Animal / Preclinical
Pharmacology supporting growth-hormone-axis activity ahead of human trials.
Early Human Evidence
Pharmacokinetic and dose-finding studies preceded the pivotal trials.
Controlled Human Research
Pivotal 412-patient Phase III RCT, plus a pooled analysis of two Phase III trials (806 participants) with safety extension data.
Established Clinical Evidence
FDA-approved (2010) for excess visceral abdominal fat in HIV-associated lipodystrophy — this indication only.
- Population/model
- 412 HIV-infected adults with excess abdominal fat
- Design
- Randomized, double-blind, placebo-controlled, Phase III
- What researchers found
- 15.2% reduction in visceral adipose tissue vs. placebo
- Major limitation
- Studies this specific population only — not generalisable beyond HIV-associated lipodystrophy
- Population/model
- 806 ART-treated adults (tesamorelin n=543, placebo n=263)
- Design
- Pooled analysis, two RCTs, 26-week treatment + 26-week safety extension
- Major limitation
- Same population as above — doesn't extend evidence to other uses
NCT00123253
The pivotal Phase III trial above. Completed, results published.
NCT00608023
Phase III extension/safety study, 263 participants. Completed, results published.
See both trials in the Clinical Trials Tracker → · Full detail on the pivotal trial →
"Tesamorelin is FDA-approved, so it's a proven way to raise growth hormone for fat loss or anti-ageing generally."
Real Phase III RCT data in a specific population (HIV-associated lipodystrophy), leading to FDA approval for that single indication.
Trial-backed efficacy for visceral fat reduction specifically in HIV-associated lipodystrophy. Not evidence for general fat loss, anti-ageing, or performance use in a different population.
Whether the same effect, dosing, and safety profile hold in people without HIV-associated lipodystrophy — a population the pivotal trials didn't study.
Limited indication-specific evidenceThe strong trial evidence is specific to HIV-associated lipodystrophy — it doesn't extend automatically to other populations.
Regulatory disagreementThe EMA reviewed essentially the same data and did not reach a positive benefit-risk conclusion for the EU market.
FDA-approved (2010) for excess visceral abdominal fat in HIV-associated lipodystrophy — this indication only. An EMA marketing authorisation application was withdrawn in 2012 after the CHMP concluded the data didn't support a positive benefit-risk balance. No MHRA authorisation has been identified for the UK, for any indication. Read the full UK regulatory framework →
What We Still Don't Know
- Whether tesamorelin would show the same effect, dosing requirements, and safety profile outside HIV-associated lipodystrophy.
- Why the EMA's risk-benefit assessment differed from the FDA's — the agencies' detailed reasoning isn't something this page can resolve.
- Long-term effects beyond the trials' safety-extension window.
Falutz J, et al., "Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV," NEJM, 2007 (DOI 10.1056/NEJMoa072375). ClinicalTrials.gov records NCT00123253 and NCT00608023, verified directly via the official registry API. FDA approval record (Egrifta, 10 Nov 2010) and EMA withdrawal documentation (2012), both verified directly against the agencies' own public records.
Evidence Library profile · Clinical Trials Tracker · UK Regulation Explained